Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.5 GBX | 0.00% | 0.00% | +9.52% |
Apr. 17 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
Apr. 17 | BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.52% | 12.03M | |
+33.59% | 50.85B | |
+0.01% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.15% | 26.11B | |
-21.93% | 19.13B | |
+8.40% | 13.05B | |
+28.18% | 12.16B | |
+24.69% | 12.08B |
- Stock Market
- Equities
- BVX Stock
- News BiVictriX Therapeutics Plc
- BiVictriX Therapeutics Secures US Patent for Lead Asset